Delving into the Latest Updates on VSA-2 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Immune System Diseases

Active Indication

Autoimmune Diseases

Inactive Indication-

Originator Organization

The University of Alabama

Active Organization

The University of Alabama

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

VSA-2 is a recently developed semisynthetic saponin immunostimulant. It is prepared by incorporating a terminal-functionalized side chain to the branched trisaccharide domain at the C3 position of Momordica saponin II (MS II) isolated from the seeds of perennial Momordica cochinchinensis Spreng. Direct comparison of VSA-2 and the clinically proven saponin adjuvant QS-21 shows that VSA-2 is comparable to QS-21 in enhancing humoral and cellular immune responses. Structure-activity relationship studies show that structural changes in the side chain have a significant impact on saponins' adjuvant activity. However, with the VSA-2 molecular framework intact, the new VSA-2 analogues with various substitution(s) at the terminal benzyl group of the side chain retain the ability of potentiating antigen-specific humoral and cellular responses.

100 Deals associated with VSA-2

Login to view more data